Lake Street analyst Thomas Flaten raised the firm’s price target on OncoCyte (OCX) to $8 from $5 and keeps a Buy rating on the shares after the company announced CMS “substantially” increased the reimbursed rate for GraftAssureCore to $2,753. The firm believes this “augurs well” for future GraftAssureDx pricing, so it has raised estimates, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCX:
- OncoCyte Corp’s Earnings Call: Optimism Amid Challenges
- OncoCyte’s Strategic Initiatives and Financial Management Drive Buy Rating
- OncoCyte Corp Reports Revenue Growth Amid Losses
- OCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OncoCyte provides update on progress toward initiating clinical trial